首页> 外文OA文献 >Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research.
【2h】

Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research.

机译:道德标准(HRpp)和公共合作伙伴关系(paRTaKE)解决印度的临床研究问题:走向道德,负责任,文化敏感和社区参与临床研究。

摘要

Like other emerging economies, India's quest for independent, evidence-based, and affordable healthcare has led to robust and promising growth in the clinical research sector, with a compound annual growth rate (CAGR) of 20.4% between 2005 and 2010. However, while the fundamental drivers and strengths are still strong, the past few years witnessed a declining trend (CAGR -16.7%) amid regulatory concerns, activist protests, and sponsor departure. And although India accounts for 17.5% of the world's population, it currently conducts only 1% of clinical trials. Indian and international experts and public stakeholders gathered for a 2-day conference in June 2013 in New Delhi to discuss the challenges facing clinical research in India and to explore solutions. The main themes discussed were ethical standards, regulatory oversight, and partnerships with public stakeholders. The meeting was a collaboration of AAHRPP (Association for the Accreditation of Human Research Protection Programs)-aimed at establishing responsible and ethical clinical research standards-and PARTAKE (Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment)-aimed at informing and engaging the public in clinical research. The present article covers recent clinical research developments in India as well as associated expectations, challenges, and suggestions for future directions. AAHRPP and PARTAKE provide etiologically based solutions to protect, inform, and engage the public and medical research sponsors.
机译:像其他新兴经济体一样,印度对独立,循证和负担得起的医疗保健的追求导致临床研究领域强劲而有希望的增长,2005年至2010年间的复合年增长率(CAGR)为20.4%。基本驱动力和优势仍然强劲,在过去几年中,由于监管机构的关注,激进主义者的抗议活动和赞助商离任,见证了下降趋势(CAGR -16.7%)。尽管印度占世界人口的17.5%,但目前仅进行了1%的临床试验。印度和国际专家以及公共利益相关者于2013年6月在新德里举行了为期2天的会议,讨论了印度临床研究面临的挑战并探讨解决方案。讨论的主题是道德标准,监管监督以及与公共利益相关者的伙伴关系。该会议是AAHRPP(人类研究保护计划认可协会)的合作,旨在建立负责任和符合道德的临床研究标准; PARTAKE(通过知识和赋权促进治疗研究的公共意识),旨在告知和参与公众从事临床研究。本文介绍了印度最近的临床研究进展以及相关的期望,挑战和对未来方向的建议。 AAHRPP和PARTAKE提供了基于病因的解决方案,以保护,宣传公众和医学研究的发起人,并与之合作。

著录项

相似文献

  • 外文文献
  • 中文文献

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号